Two innovation signals pointed toward scaling translational biology infrastructure. First, Geneseeq’s Fragmentia-AI platform introduced a computational approach to fragmentomic cell-free DNA analysis that is designed to generalize across platforms and tumor types, with a small pilot study suggesting cancer detection performance under ultra-low-pass sequencing contexts. Separately, Bioptimus partnered with the Fédération Francophone de Cancérologie Digestive to expand access to multimodal spatial tissue atlas data, gaining trial and spatial omics material from more than 3,000 gastrointestinal patients. Together, the updates emphasize pipeline acceleration not just through molecules, but through the data and measurement layers that inform target selection, response modeling, and biomarker strategy. Both developments reflect how biotech is increasingly investing in “measurement capacity” alongside discovery and clinical execution.